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We conclude that some MS lesions fail to remyelinate sec-
ondary to reduced OPC recruitment, and that chemotactic 
molecules are involved in the mechanism, providing a new 
group of drug targets to improve remyelination, with a spe-
cific target in the Sema3A receptor neuropilin-1.
Keywords Remyelination · Semaphorin · Migration · 
Oligodendrocyte precursor cell
Introduction
The quest for discovery of molecules that improve CNS 
remyelination is prompted by the premise that this will not 
only help repair demyelinated lesions in multiple sclerosis 
(MS), aiding symptoms by overcoming conduction block 
and temporal dispersion of action potentials by restoring 
saltatory conduction, but also protect axons from neuro-
degeneration which causes progressive disability [8, 24]. 
Myelinating oligodendrocytes have been shown to be 
trophic for axons, providing them with necessary metabolic 
support [14, 25]. Remyelination does occur in MS brain, 
but is inefficient and inadequate [34–36, 38, 40]. For remy-
elination to occur, oligodendrocyte precursor cells (OPCs) 
must survive, proliferate, migrate to the lesion and dif-
ferentiate into mature oligodendrocytes forming compact 
myelin sheaths [12]. Failure of remyelination may occur at 
any step in this process, but it is thought to be mostly due 
to failure or arrest of oligodendroglial differentiation. This 
is partly due to pathological studies revealing that 60–70 % 
of demyelinated MS lesions contain oligodendroglial cells 
in an arrested maturation state [6, 27] and is reflected in 
the molecules now associated with altering CNS remyeli-
nation in rodents, which all promote oligodendroglial mat-
uration: 9-cis retinoic acid [17], anti-Lingo-1 antibodies 
Abstract Failure of remyelination of multiple sclerosis 
(MS) lesions contributes to neurodegeneration that cor-
relates with chronic disability in patients. Currently, there 
are no available treatments to reduce neurodegeneration, 
but one therapeutic approach to fill this unmet need is to 
promote remyelination. As many demyelinated MS lesions 
contain plentiful oligodendrocyte precursor cells (OPCs), 
but no mature myelinating oligodendrocytes, research has 
previously concentrated on promoting OPC maturation. 
However, some MS lesions contain few OPCs, and there-
fore, remyelination failure may also be secondary to OPC 
recruitment failure. Here, in a series of MS samples, we 
determined how many lesions contained few OPCs, and 
correlated this to pathological subtype and expression of the 
chemotactic molecules Semaphorin (Sema) 3A and 3F. 37 % 
of MS lesions contained low numbers of OPCs, and these 
were mostly chronic active lesions, in which cells expressed 
Sema3A (chemorepellent). To test the hypothesis that dif-
ferential Sema3 expression in demyelinated lesions alters 
OPC recruitment and the efficiency of subsequent remyeli-
nation, we used a focal myelinotoxic mouse model of demy-
elination. Adding recombinant (r)Sema3A (chemorepel-
lent) to demyelinated lesions reduced OPC recruitment and 
remyelination, whereas the addition of rSema3F (chemoat-
tractant), or use of transgenic mice with reduced Sema3A 
expression increased OPC recruitment and remyelination. 
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[30], Wnt inhibition [10], axin-2 stabilization [11], loss of 
cdk2 [2], noggin [42], antibodies antagonizing death recep-
tor-6 [29] and CXCR4 [3]. The effect of these molecules in 
humans is not known and only anti-Lingo antibodies have 
reached clinical trial in MS (Clinicaltrials.gov identifier 
NCT01244139).
Molecules affecting other processes necessary for 
remyelination, such as migration, have been less studied 
in spite of a third of demyelinated MS plaques containing 
few OPCs [6, 27]. Group 3 semaphorins are secreted fac-
tors that attach to extracellular matrix forming gradients for 
cells to use as migration cues. Sema3A binds to the recep-
tor Neuropilin (NP)1 and Sema3F to the receptor NP2, and 
in development, Sema3A is an inhibitory and Sema3F an 
attractive migratory signal for OPCs [43, 45]. We have pre-
viously shown that in adulthood, Sema3A and 3F mRNA 
expression is absent in white matter, but re-expressed in MS 
lesions in a differential way in different lesions, with active 
lesions (more inflammatory and more likely to remyelinate) 
containing higher mRNA expression of the chemoattract-
ant Sema3F than Sema3A, and chronic active lesions (less 
inflammatory and less likely to remyelinate) with higher 
mRNA expression of the chemorepellent Sema3A than 
Sema3F [54]. Here, we assessed the number of OPCs in our 
series of MS lesions in postmortem tissue, and correlated 
these with pathological classification and Sema3A/Sema3F 
protein expression. We found a correlation between a lower 
number of OPCs, chronic active lesion type and a higher 
expression of the chemorepellent protein Sema3A. In con-
trast, a low expression of the chemorepellent Sema3A and 
higher expression of the chemoattractant Sema3F corre-
lates with active lesions and more variable, but generally 
higher OPC numbers. We then tested the hypothesis that 
the mechanism for these observations is due to the effect 
of these chemotactic factors on OPC migration and sub-
sequent remyelination by manipulating levels of Sema3A 
or 3F in a mouse model of demyelination. We conclude 
that migration failure is an important cause of remyelina-
tion failure and introduce the Sema3A/NP1 pathway as a 
possible therapeutic target to improve OPC migration and 
remyelination in MS.
Materials and methods
Animal work was carried out in accordance with the Univer-
sity of Edinburgh regulations under Home Office rules, with 
local ethics committee consent.
MS brain samples
Postmortem unfixed frozen tissue was obtained from the 
UK Multiple Sclerosis Tissue Bank via a UK prospective 
donor scheme with full ethical approval (MREC/02/2/39). 
Two independent researchers characterized the lesion types 
as active, chronic active, chronic inactive or remyelinating 
[48]. Active plaques have indistinct borders on Luxol fast 
blue (LFB) staining, and inflammatory cells throughout the 
lesion (mostly large, round, and lipid-laden macrophages/
microglia). Chronic active lesions have a demyelinated 
core with few inflammatory cells, but a ring of lipid-laden 
macrophages/microglia at their edge. Chronic inactive 
lesions have a sharp edge on LFB and few inflammatory 
cells throughout. We analyzed active (n = 9), chronic active 
(n = 6), chronic inactive (n = 8) and remyelinated (shadow) 
(n = 7) MS plaques from 15 blocks of brain tissue from 10 
MS patients and 5 blocks from 5 controls with no neurologi-
cal disease (Table 1).
Immunohistochemistry/fluorescence
Colorimetric labelling (EnVision+, Dako) was used to 
see patterns of staining and immunofluorescence labelling 
to identify the cells expressing each molecule of interest, 
in regions of interest. Human postmortem tissue is much 
more difficult to use than mouse perfused tissue/cultures 
and required antigen retrieval by microwaving in Vector 
H-3300 antigen unmasking solution (Vector Laboratories) 
for 10 min, and for immunofluorescence, autofluorescence 
was partially suppressed using 0.01 % sudan black in 70 % 
ethanol for 10 min. OPCs in human tissue were identi-
fied either using Nkx2.2 antibodies for tissue processed 
for immunofluorescence (rabbit, 1 in 200, Developmental 
Studies Hybridoma Bank, University of Iowa, USA), or 
using a combination of being positive for Olig2 expression 
(goat, 1 in 100, R and D systems, or rabbit 1 in 100, Sigma) 
and negative for NogoA expression (Mouse 1 in 100, R and 
D systems), for colorimetric staining. Antibodies to NG2 or 
PDGFRα do not work reliably in our hands in human fro-
zen tissue. Other antibodies: CD68 (rat, 1 in 200, Abcam), 
cleaved caspase-3 (rabbit, 1 in 300, Cell Signaling), GFAP 
(glial fibrillary acidic protein, chick, 1 in 500, Covance), 
Ki67 (rabbit, 1 in 400, Novocastra), myelin basic protein 
(MBP, rat, 1 in 300, Serotec), neurofilament (NF–H, chick, 
1 in 50,000, Covance), Neuronin N (NeuN, mouse, 1 in 
300, Millipore), Neuropilin-1 (Rabbit, 1 in 50, CST), Neu-
ropilin-2 (Goat, 1 in 50, R and D systems), NG2 (mouse, 
or rabbit, 1 in 200, Millipore), Sema3A (rabbit, 1 in 100, 
Abcam), Sema3F (rabbit, 1 in 50, Millipore). Appropriate 
fluorescent secondary antibodies were used (AlexaFluor, 
Invitrogen).
For quantification of numbers of OPCs in MS lesions, 
consecutive 8-μm cryostat sections of MS tissue or tissue 
from normal controls were stained with Olig2 and NogoA 
antibodies and numbers of single and double-positive cells 
in each field of view calculated. At least three fields of 
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view (each sized 0.2 mm2) were measured for each lesion, 
increasing up to 11 fields of view for the largest lesions. 
The normal range of OPC number was defined as the 
mean ± one standard deviation of OPC counts from 35 
fields of view of white matter from blocks from five differ-
ent normal controls.
For measurement of numbers of nkx2.2+, CC1+, Ki67+ 
(proliferation) or cleaved caspase-3+ cells (apoptosis) 
in cryostat sections, we counted the number of Ki67+ or 
cleaved caspase-3 + cells per unit area of the lesion and 
contralateral normal tissue in the corpus callosum on the 
same section, using a minimum of 20 sections from four 
mice per treatment group. Statistical analysis: ANOVA for 
multiple comparisons with Tukey’s post test and the non-
parametric Mann–Whitney test for two group comparisons, 
with a p < 0.05 considered as statistically significant.
Surgery
Wild-type mice
Using anaesthetized 12-week-old C57Bl/6 male mice, 
2 μl of 1 % lysophosphatidyl choline/lysolecithin (LPC) 
was injected through a hole drilled in the skull at ste-
reotactic coordinates 1.2 mm posterior, 0.5 mm lateral, 
1.4 mm deep to the bregma over 4 min using a 30 gauge 
needle attached to a Hamilton syringe, driven by a KD 
Scientific Nano pump, which was left in situ for 4 min 
to reduce backflow. MR scans were performed 4 days 
later to select mice with demyelinating lesions of similar 
sizes—a minimum of five mice was chosen for each treat-
ment and time point (48 in total). Injection of 10 μg/ml 
of rSema3A/rSema3F/saline (all mixed with 10 μg/ml 
Laminin) was similarly carried out on day 6. Mice were 
perfused with 4 % PFA at 2, 3 or 4 weeks. Fixed brains 
were bisected coronally at the injection site, with the ante-
rior portion processed for cryosectioning, and the poste-
rior portion for electron microscopy.
To isolate tissue for Western Blot quantification of 
Sema3A/Sema3F protein in demyelinating lesions, unfixed 
brains were removed from mice at days 3 and 7 after LPC 
injection, the lesion area dissected out and compared with 
an equivalent area of non-lesioned corpus callosum. Further 
time points were not included as after post-injection day 7, 
we could no longer determine the exact site of the lesion 
under a dissection microscope due to remyelination. West-
ern Blots were carried out using Sema3A antibody 1:1000, 
Abcam, Sema3F antibody 1:500, Millipore and GAPDH 
1:10,000, Sigma, as a loading control. For quantification, 
the density of bands from two blots from two experiments 
was compared using Image J.
Knockdown mice
To produce transgenic mice expressing reduced levels of 
Sema3A (Sema3AKD), we crossed Sema3A floxed mice 
(Riken RBRC01106) with a mouse expressing Cre recom-
binase under the HPRT promoter (from L. Smith, Edinburgh 
University, Edinburgh) (both on a CD1 background), and 
confirmed the genotype by PCR (http://www2.brc.riken.jp/
animal/pdf/01106_PCR.pdf). Knockdown of Sema3A 
Table 1  Characteristics of MS brain blocks analyzed
Patient Sex Age (years) MS type Disease duration 
(years)
Time to postmortem  
(h)
No. of MS 
lesions
Active Chronic 
active
Chronic 
inactive
MS100 M 46 SP 8 7 11 1 0 7
MS121 F 49 SP 14 24 3 2 1 0
MS136 M 40 SP 9 10 9 1 0 3
MS147 F 60 SP 21 27 3 1 1 1
MS154 F 34 SP 21 12 4 2 0 1
MS176 M 37 PP 27 12 7 0 0 2
MS187 F 57 SP 27 13 4 0 0 0
MS207 F 46 SP 25 10 8 0 3 3
MS230 F 42 SP 19 31 4 2 0 0
MS242 F 57 SP 19 12 6 0 3 3
Control
 CO11 M 77 26
 CO14 M 64 18
 CO25 M 35 22
 CO28 F 60 13
 CO39 M 82 21
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protein was confirmed using Western Blot (Sema3A anti-
body 1:1000, Abcam, GAPDH 1:10,000, Sigma, as a load-
ing control). For quantification, the density of bands from 
three blots was compared using Image J. 12-week-old male 
Sema3AKD mice and their littermates not expressing Cre 
(as controls), were used for surgery as above, with five mice 
for each group and time point.
Magnetic resonance imaging
MRI data were collected on anaesthetized, monitored mice 
using an Agilent 7T preclinical scanner (Agilent Technolo-
gies), with a 72 mm volume coil and a phased array mouse 
brain coil (Rapid Biomedical). Twenty-nine contiguous cor-
onal T2-weighted fast-spin echo images (echo train length 
8) of 0.4-mm slice thickness were collected with the follow-
ing parameters: repetition time (TR) = 3,000 ms; effective 
echo time = 36 ms; field of view = 19.5 mm × 19.5 mm; 
matrix = 192 × 192; 6 signal averages; total scan time 
7 min 18 s.
Semi-thin sections and transmission electron microscopy 
(EM)
1-mm thick coronal section samples were post-fixed in 
4 % PFA containing 0.5 % glutaraldehyde for 1 h, then 
2 % PFA/2 % glutaraldehyde at 4 °C overnight and pro-
cessed into resin blocks using standard protocols. Sagittal 
1-μm semi-thin sections were stained with toluidine blue 
to select suitable areas for investigation. Ultra-thin sections, 
60 nm thick, were stained in uranyl acetate and lead citrate. 
Semi-thin sections were taken throughout the lesion (all of 
similar size on MR) and mounted onto one slide per animal. 
These slides were ranked for those with the most myelinated 
profiles in the lesion to those with the least by two blinded 
observers. No attempt was made to assign a value to the 
proportion of remyelination, but simply to establish how a 
lesion ranked relative to others, as validated and used previ-
ously [17, 41, 55]. To confirm this ranking, we examined 
ultra-thin sections for the percentage of myelinated fibres, 
and the thickness of myelin sheaths. The mean percent-
age of myelinated fibres was measured from 10 fields per 
animal, accounting for at least 500 fibres. The thickness 
of myelin around myelinated fibres was expressed as a 
g-ratio (axon perimeter divided by myelinated fibre perim-
eter) to accommodate that myelin is thicker around larger 
axons than smaller axons. This was measured using Image 
J by tracing around a minimum of 100 individual fibres per 
lesion, including all myelinated fibres in each field, to avoid 
bias, using a pen and electronic pad (Bamboo pad, Wacom). 
Statistical analysis: ANOVA and post test Tukey’s multiple 
comparison test, with a p < 0.05 considered as statistically 
significant.
Results
OPC number in MS lesions
Many papers state that the cause of remyelination failure in 
MS is due to arrest of oligodendroglial maturation within 
a demyelinated plaque, as most MS lesions contain suffi-
cient OPCs. Previously, the largest series of counts of OPCs 
in lesions suggested that around 70 % of plaques had suf-
ficient or plentiful OPCs, and 30 % few OPCs [27]. The 
best way to identify an OPC in human postmortem tissue 
has been debated, mostly due to the unreliability of stain-
ing using antibodies to NG2, PDGFRα and Nkx2.2 in this 
tissue, which is difficult to use. However, as used in [21], 
a combination of positive staining with Olig2 (a nuclear 
marker which stains OPCs and more mature oligodendro-
cytes) and a lack of staining with NogoA (cytoplasmic 
staining in mature oligodendrocytes) provides reliable stain-
ing throughout MS tissue (Fig. 1a–c).
We used this method to assess the number of OPCs 
throughout lesions from postmortem MS tissue obtained 
from the UK MS Tissue Bank. We analyzed active (n = 9), 
chronic active (n = 6), chronic inactive (n = 8) and remy-
elinated (shadow) (n = 7) MS plaques from 15 blocks of 
brain tissue from 10 MS patients and five blocks from five 
controls (Table 1). Active plaques are thought to have more 
propensity to remyelinate as compared to chronic plaques 
and chronic active plaques occupy the middle zone. The 
normal range of numbers of OPC in the brain was defined 
as the mean ± one standard deviation of OPC counts from 
35 fields of view from five blocks from five different post-
mortem brains, where death was due to a non-neurological 
cause (mean 95 ± 23 SD).
We found that in MS lesions, the average OPC count 
(Olig2+/NogoA−) per lesion for active lesions was higher 
than normal in 5/9 lesions examined, with one within 
the normal range and three with low counts. In remyeli-
nated lesions, OPC number was higher than normal in 3/7 
lesions, with one within the normal range and three with 
low counts. For chronic inactive lesions, one lesion had 
a count just higher than normal, 5/6 lesions had a nor-
mal OPC count, with two with a low count. However, 5/6 
chronic active lesions had lower than normal counts, with 
one just reaching the normal range. Therefore, in total, 
11/30 (37 %) of MS lesions in our sample had insufficient 
OPCs, and although this occurred in every lesion type, 
most chronic active lesions contained few OPCs (Fig. 1d). 
This confirms the previous results [27], and rebuts the idea 
that OPC maturation failure is the only important cause of 
remyelination failure in MS. Furthermore, we noted that 
the density of OPCs in lesions was variable within dif-
ferent areas of the lesion (Fig. 1e), which is rarely con-
sidered although it has been described previously [5]. 
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This was true of all types of lesions, and we found no 
correlation of local number of OPCs and position within 
the lesions (e.g., centre or edge) nor with the density of 
microglia/macrophage infiltrate. In comparison, OPC 
densities appeared less variable in white matter in control 
non-MS brains.
Chronic active Active Chronic active 
x
Chronic active Active e
a b cOlig2 NogoA Olig2/NogoA
Lesion Type
Remyelinated Control non MS WM Control non MS WM Chronic inactive 
d
Normal 
range
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ar
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Fig. 1  Different human MS lesions contain different numbers of 
OPCs. Colorimetric staining of an active MS lesion showing a 
Olig2+ cells, b NogoA+ cells and c immunofluorescence showing 
dual labelling (Olig2 in green and NogoA in red). The thick arrow 
shows an Olig2+ cell and the thin arrow a dual labelled cell. Scale 
bar a and b 40 μm c 10 μm. d Bar graph of average OPC num-
ber per lesion area, with one bar per lesion, showing the variation 
between pathological subtypes, with fewer OPCs in the chronic 
active lesions. The normal range of numbers of OPC in the brain was 
defined as the mean ± one standard deviation of OPC counts from 
35 fields of view from 5 blocks from 5 different postmortem brains 
where death was due to a non-neurological cause. e Schematic show-
ing the variability of OPC number in different regions of single 
lesions represented as white (for demyelinated lesions) or pale grey 
areas (for remyelinated lesions) compared with white matter of con-
trol non-MS brain tissue. Red boxes represent fields of view counted, 
and 1 grey circle represents 10 OPCs
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Sema3A and Sema3F are differentially expressed in MS 
lesions
The existence of lesions containing few OPCs, and the pre-
dominance of chronic active lesions in this group, which are 
thought to be less likely to remyelinate, raised the hypothe-
sis that these lesions may be either expressing a chemorepel-
lent for OPCs, or failing to express a chemoattractant, thus 
reducing OPC recruitment. Our previous work showed that 
the chemotactic factors Sema3A and 3F are re-expressed in 
MS lesions at the mRNA level, as compared to control white 
matter [54]. However, the protein expression of Sema3A or 
3F has not previously been described in adult human brain in 
either normality or pathology. We used colorimetric staining 
to identify patterns of Sema3A/3F expression in lesions, and 
immunofluorescence to focus in on which cells expressed 
these molecules.
Normal control brain tissue showed expression of Sema3A 
and 3F protein in neuronal cell bodies plus Sema3A in some 
axons in the grey matter (Fig. 2a, b), but no detectable 
expression in the white matter. In active plaques, Sema3F 
was present in and around the lesion, labelling both astro-
cytes and microglia/macrophages, but virtually no Sema3A 
protein expression was seen, despite the positive staining on 
the same sections in neurons in the grey matter (Fig. 2a), 
with only an occasional perivascular Sema3A-positive cell 
seen. However, in chronic active lesions, there was both 
Sema3F and 3A staining (again in astrocytes and microglia/
macrophages) with more Sema3A present at the active rim. 
Chronic inactive MS plaques contained a few Sema3A or 
3F-positive microglia/macrophages only. Remyelinated 
plaques contained very few Sema3A or Sema3F-positive 
microglia/macrophages only (Figs. 2c, d, 3a).
Thus, we have found a correlation between the activity 
of a MS lesion, defined pathologically, and the presence of 
expression of the chemorepellent Sema3A. We found that the 
number of OPCs present in any lesion inversely correlated 
with the density of Sema3A-positive cells in that lesion, but 
that the pattern was less clear for Sema3F expression and 
OPC number (Fig. 2e). As we showed in Fig. 1d that OPC 
numbers are variable between lesions even of the same path-
ological subtype, we compared the number of cells express-
ing Sema3A and 3F in each lesion grouped by subtype, with 
the number of OPCs found in that lesion (Fig. 2f). Although 
there is individual variation, there is again a pattern that the 
presence of Sema3A-positive cells in the lesion correlates 
with low OPC numbers, and that these are mostly chronic 
active lesions. There is less correlation between the num-
ber of cells expressing the chemoattractant Sema3F and the 
number of OPCs, although active lesions generally contain 
less Sema3A+ cells, more Sema3F+ cells and more OPCs.
Therefore, the presence of the chemorepellent Sema3A 
correlates with fewer OPCs in the lesion, and a chronic 
active pathological subtype, which has a lower propensity 
to remyelinate.
OPCs express the receptors for Sema3A and 3F
Sema3A and 3F bind to the transmembrane receptors 
Neuropilin (NP) one or two respectively. These receptors 
are distinct though chemically related, with no crosso-
ver in binding of the Sema3A or 3F ligands [15]. OPCs in 
human MS tissue express the neuropilin receptors (Fig. 3b), 
although these receptors are also expressed by microglia/
macrophages and astrocytes in all MS lesion types (Suppl. 
Fig. 1) except remyelinated lesions (data not shown).
Sema3A and 3F expression are regulated in demyelinating 
lesions in mouse
These human data suggest that failure of OPC recruitment is 
important in a subset of MS lesions, and that the mechanism 
of this may involve Sema3A and 3F. However, research on 
human postmortem MS tissue is by its nature confined to 
one time point, so we turned to a model of demyelination in 
the mouse to investigate whether this correlation was causal.
First, we investigated whether Sema3A and 3F were 
expressed in a similar manner in demyelinated lesions in 
mouse. We created demyelinated lesions in the right side of 
the mouse corpus callosum by stereotactic injection of LPC 
Fig. 2  MS lesions with different pathology show different patterns of 
protein expression of Sema3A and 3F. In normal human brain grey 
matter, there is expression of Sema3A protein in neuronal cell bodies 
and some axons (a) and Sema3F (b) in neuronal cell bodies by col-
orimetric and immunofluorescence staining (green Sema3A/F label-
ling, red NeuN staining neuronal cell bodies). c Colorimetric staining 
shows patterns of staining in active, chronic active or chronic inactive 
MS lesions. There is absence of Sema3A staining, but florid Sema3F 
staining in active lesions, as compared to more chronic lesions, 
which express both proteins. Scale bars 10 μm. d Quantification of 
the number of cells in each type of MS lesion expressing Sema3A 
or Sema3F/unit area confirms that there are few cells in active 
lesions expressing Sema3A, but more expressing Sema3F, whereas 
in chronic active lesions, more cells express Sema3A compared with 
Sema3F, and chronic inactive and remyelinated lesions have few 
cells expressing either protein. e For each lesion, the number of cells 
expressing Sema3A or Sema3F is plotted against the average num-
ber of OPCs in the lesion, to identify a correlation. The normal range 
of number of OPCs is shown as defined as the mean ± one standard 
deviation of OPC counts from 35 fields of view from 5 blocks from 5 
different postmortem brains where death was due to a non-neurolog-
ical cause. An increase in number of cells expressing Sema3A corre-
lates with fewer OPCs found in the lesion, whereas the relationship is 
less clear with Sema3F. f Graph showing numbers of cells expressing 
Sema3A or Sema3F and the average number of OPCs in each lesion, 
separated by pathological subtype. The normal range of OPC number 
is marked, as described above. Although there is variability between 
lesions, if the lesion contains more Sema3A-expressing cells (red), 
the OPC number is lower, and high numbers of OPCs are only pre-
sent if the number of Sema3A-expressing cells is low
▸
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(Fig. 4) and confirmed the presence of an appropriately sized 
and placed lesion by MR scanning. In this model, demyeli-
nation is complete around 3 days, migration of OPCs into the 
lesion starts at around day 6, the differentiation phase occurs 
around days 10–14 and remyelination is usually complete 
by about 4 weeks [17, 55], as remyelination failure does not 
occur. Sema3A and 3F are not expressed at the protein or 
mRNA level by immunofluorescence or in situ hybridiza-
tion [54] in normal white matter in adult mice. Sema3A pro-
tein is detectable throughout demyelinated lesions at 3 days 
after LPC injection (PID3), but is reduced and limited to the 
lesion edge after 7 days (PID7). Sema3F protein expression 
Fig. 3  Astrocytes and micro-
glia/macrophages express 
Sema3A, 3F in MS brain, and 
oligodendroglial cells express 
their receptors a Astrocytes 
(GFAP-labelled) and microglia/
macrophages (CD68-labelled) 
in chronic active lesions express 
Sema3A. Astrocytes and micro-
glia/macrophages in active and 
chronic active lesions express 
Sema3F (active lesion shown)  
b NP1 and NP2 are expressed in 
oligodendroglial cells (Nkx2.2-
labelled) (chronic active lesions 
shown). Examples of double-
positive cells are labelled with 
arrows. Pictures are flattened 
confocal stacks. White boxes 
indicate location of magni-
fied picture. High background 
staining is found in this human 
postmortem tissue and is most 
obvious in the NP2 photographs 
where the bright punctate stain-
ing is nonspecific. Scale bar 
10 μm
Sema3F GFAP
Sema3A GFAP
Sema3A CD68
Sema3F CD68
a
b
merge
merge
merge
merge
NP1 Nkx2.2 merge
NP2 Nkx2.2 merge
magnified
magnified
magnified
magnified
magnified
magnified
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is patchy within the lesion at day 3 (PID3), declining in a 
similar, but slower manner from the inner core of the lesion 
outwards, leaving a positive rim. By day 14 (PID14), both 
Sema3A and 3F staining is absent (Fig. 5a). We confirmed 
this transient increase in expression of Sema3A by Western 
Blot analysis (Fig. 5b, c). As in human MS lesions, we found 
that the cells expressing Sema3A or 3F in these lesions were 
astrocytes and microglia/macrophage and that some OPCs 
expressed NP1 and NP2 (Fig. 6).
Adding rSema3A or 3F to demyelinated lesions in mouse 
alters OPC recruitment
As semaphorins are re-expressed after demyelination in 
mouse, similarly to in human MS lesions, we hypothesized 
that manipulation of the levels of Sema3A or 3F to a demy-
elinated lesion would alter OPC recruitment and hence 
remyelination.
Six days after lesion induction, when demyelination is 
complete and migration of cells into the lesion starts [55], 
we injected recombinant (r)Sema3A, rSema3F or saline 
into the lesion mixed with laminin, to which Sema3A and 
3F bind [7, 9], to aid maintenance of a high concentration 
local to the lesion. We then examined the lesions at 2, 3 and 
4 weeks (Fig. 7a).
At 2 weeks, both control and rSema3F-injected mice 
showed an increased number of nkx2.2+ OPCs around the 
lesion as compared to the non-lesion side, presumably due 
to up-regulation of endogenous pro-migration molecules 
locally in control lesions. However, at this time point, rSe-
ma3A treated mice had significantly fewer OPCs on the 
lesion side as compared to the opposite side, indicating a 
repulsive effect that overcomes even these endogenous pro-
migration factors. The effect of rSema3A is maintained even 
4 weeks after the lesion with still fewer OPCs on the treated 
side. In animals treated with rSema3F, the increase in OPCs 
b c
100µm
d e
Grey matter 
Grey matter 
Corpus callosum 
a
MBP GFAP Olig2 merge
MBP GFAP Olig2 merge
e
Fig. 4  Demyelination in our mouse model a typical demyelinated 
lesion shown by Luxol fast blue staining: demarcated by dashed line. 
Scale bar 100 μm. b Typical lesion shown by fluoromyelin green 
staining (composite photo)—demarcated by dashed line. Scale bar 
200 μm. c Semi-thin section stained with toluidine blue showing a 
lesion, delineated with red dashed line, in the corpus callosum deline-
ated with white dashed line. Scale bar 100 μm. Immunofluorescence 
staining of normal side (d) and lesioned side e of corpus callosum 
with antibodies against MBP (green), Olig2 (white), GFAP (red) and 
a merge with Hoechst to stain nuclei (blue). Scale bar 10 μm
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Fig. 5  Sema3A and 3F expres-
sion in our mouse model of 
demyelination. a Immuno-
fluorescence for Sema3A or 
Sema3F in a mouse lesion at 
post-injection days (PID) 3, 
7 and 14, with Sema3A or 
Sema3F (green), Hoechst to 
stain cell nuclei (blue) and a 
merge. The lesion is delineated 
by a red line. Scale bar 100 μm. 
Western blot analysis confirms 
this transient rise in expression 
for Sema3A (b) and Sema3F 
(c). C control unlesioned corpus 
callosum, PID 3,7 shown. 
GAPDH is loading control. 
Densitometry blots from 2 sepa-
rate sets of animals for each, 
showing mean density ratio 
plus SD of Sema3A/F band to 
GAPDH band, with ratio in 
unlesioned tissue defined as 1 
(*p < 0.05, **p < 0.01, t test, 
when compared with control)
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Fig. 6  Astrocytes and micro-
glia/macrophages express 
Sema3A, 3F in demyelinated 
lesions in our mouse model, and 
oligodendroglial cells express 
their receptors a Astrocytes 
(GFAP-labelled) and microglia/
macrophages (CD68-labelled) 
in demyelinated lesions at 
post-injection day 3 express 
Sema3A. b NP1 and NP2 are 
expressed in oligodendroglial 
cells (nkx2.2-labelled) at post-
injection day 3. Pictures are 
flattened confocal stacks. Scale 
bar 10 μm
Sema3A CD68 Merge with Hoechst
GFAP Merge with Hoechst
GFAPSema3F Merge with Hoechst
Sema3F CD68 Merge with Hoechst
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is maintained at 3 weeks, whereas in controls the number 
normalizes, but at 4 weeks, the numbers in rSema3F-treated 
mice are indistinguishable from controls (Fig. 7b).
The number of CC1+ mature oligodendrocytes in lesions 
increased in the control group and in those treated with rSe-
ma3F in line with an increase of OPC migration into these 
lesions and their subsequent differentiation and remyelina-
tion. However, the numbers of CC1+ cells in lesions treated 
with Sema3A remained significantly reduced, corresponding 
to reduced OPC migration and therefore less OPCs to then 
differentiate (Fig. 7b). If this reduced number of CC1+ cells 
in rSema3A-treated lesions is purely an effect of reduced 
differentiation of OPCs, as previously suggested [46], then 
we would expect a normal or increased number of OPCs in 
the rSema3A-treated lesions, rather than a reduction. Dif-
ferences in OPC number were also not due to differences 
in OPC proliferation or apoptosis as there was no differ-
ence in the number of Ki67+ or cleaved caspase-3+ cells 
Fig. 7  Manipulation of 
Sema3A or Sema3F levels 
in the mouse model in vivo 
changes OPC migration to 
the lesion. a Timeline for 
experiment. b More nkx2.2+ 
oligodendroglial cells are 
present around and within 
lesions treated with rSema3F 
and less around lesions treated 
with rSema3A as compared 
to the unlesioned sides at 2 
and 3 weeks after the lesion. 
More CC1+ oligodendrocytes 
are present around and within 
lesions treated with rSema3F 
and less around lesions treated 
with rSema3A as compared to 
the unlesioned side at 3 and 
4 weeks after the lesion (mean 
ratio + SD asterisks on bars 
indicate value is significantly 
different as compared to con-
tralateral side (assigned value of 
1), symbols above bars indicate 
significant differences between 
groups *p < 0.05, $p < 0.001, 
ϕp < 0.01, comparing treatments 
by ANOVA and Tukey’s post 
test). There is no difference in 
proliferation (Ki67+ cells) c or 
apoptosis (cleaved caspase-3+ 
cells) d within the lesion 
between the groups at 2 weeks 
(mean + SD, n > 20 sections 
from 5 mice per group)
Day 1
Stereotactic 
injection of LPC 
into corpus 
callosum
Day 4
MR scan
Day 6
Stereotactic 
injection of 
  Sema3A, Sema3F
or control into 
corpus callosum
Week 2, 3 or 4 
post-LPC injection: 
harvest brain
*
Semi-thin/EM
Cryosection
a
b
Ø
Ø
$
0
1
2
3
4
N
o.
 
K
i6
7+
 c
el
ls
/u
n
it 
ar
ea
Control
*
*
*
c
0
0.5
1
1.5
2
2.5
Control Sema3A Sema3F Control Sema3A
3 weeks
.Sema3F Control Sema3A
4 weeks
Sema3F
R
at
io
 o
f i
ps
ila
te
ra
l c
el
ls 
to
 c
on
tra
la
te
ra
l Nkx2.2+ cells
CC1+cells
2 weeks
* * * * ** *
*
2 weeks
0.0
0.1
0.2
0.3
N
o.
Ca
sp
3+
 c
el
ls
/u
n
it 
ar
ea
d
2 weeks
n=65 mice n=5 or 6 mice 
per group
Sema3A Sema3F Control Sema3A Sema3F
853Acta Neuropathol (2013) 125:841–859 
1 3
in the lesions between groups. At 2 weeks after the lesion, 
when most proliferation and death would be expected, there 
were few cells undergoing proliferation or apoptosis, and 
only very rarely were these found to be OPCs (Fig. 7c, d, 
Suppl. Fig. 2).
Adding rSema3A and 3F to demyelinated lesions in mouse 
alters remyelination
Thus, we can manipulate the number of OPCs that are 
recruited to mouse demyelinated lesions using rSema3A or 
3F, but we next asked whether this difference in recruitment 
translated into a difference in remyelination efficiency. We 
assessed the extent of remyelination in these lesions at 2 
and 4 weeks using a previously described blinded ranking 
system [17, 41, 55] (see methods) (Fig. 8a), by measuring 
the percentage of fibres which were myelinated (Fig. 8b) 
and the thickness of these myelinated fibres (Fig. 8c). The 
ranking measure showed an improvement of remyelina-
tion with Sema3F treatment and reduced remyelination 
with Sema3A treatment. At 2 weeks, there was no differ-
ence between the numbers of fibres myelinated between the 
groups, but the myelin was significantly thinner in those 
mice treated with the chemorepellent Sema3A (mean g-ratio 
0.81 ± 0.010 (SEM), as compared to control and Sema3F 
(mean 0.76 ± 0.010 SEM and mean 0.75 ± 0.011 SEM, 
respectively). At 4 weeks, there was a clear difference in the 
percentage of myelinated fibres between groups, with con-
trol and Sema3F-treated mice reaching normal levels [23] 
(mean 70.9 % ± 2.9 SEM and mean 75.1 % ± 2.1 SEM, 
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Fig. 8  Manipulation of Sema3A or Sema3F levels in the mouse 
model in vivo changes remyelination efficiency. a Blinded rank-
ing of remyelination shows improved remyelination with addition 
of rSema3F and an inhibition of remyelination with addition of rSe-
ma3A to the lesion. Horizontal line represents median (**p < 0.01 
and *p < 0.05 using 1-way ANOVA and Tukey’s post test.) b Graph 
of percentage of myelinated fibres in each group, counted from 
10 fields of view per animal, and at least 500 fibres per group. This 
shows that there is no difference between the number of fibres myeli-
nated at 2 weeks, but there is a clear difference at 4 weeks, with no 
increase in myelinated fibres in the Sema3A-treated group over this 
time. In contrast, the number of myelinated fibres returns to normal 
levels for the corpus callosum in control and Sema3F-treated animals 
(mean ± SEM ***p < 0.001, **p < 0.01 and *p < 0.05 using 1-way 
ANOVA and Tukey’s post test). c Graph showing that the average 
g-ratio per animal in each group is significantly higher in Sema3A-
treated animals at both time points, indicating thinner myelin than in 
the other two groups. Sema3F-treated animals have a trend to thicker 
myelin by 4 weeks (lower g-ratio). Note that the y-axis is inverted and 
does not start at zero, so that the graphs in a, b and c can be directly 
compared (mean ± SEM ***p < 0.001, **p < 0.01 and *p < 0.05 
using 1-way ANOVA and Tukey’s post test). d Electron microscope 
photographs through lesions. Scale bar 1 μm
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respectively), whereas in Sema3A-treated mice the percent-
age remains low (mean 18.7 % ± 4.3 SEM) and unchanged 
to that at 2 weeks. At 4 weeks, Sema3A-treated mouse 
remyelinated axons remain significantly thinner (mean 
g-ratio 0.82 ± 0.004 SEM) than in control (mean g-ratio 
0.76 ± 0.009 SEM) and Sema3F-treated groups (mean 
g-ratio 0.72 ± 0.007 SEM). Although not statistically sig-
nificant, Sema3F-treated mice remyelinated axons have 
a trend to having thicker myelin than controls at both 2 
and 4 weeks, perhaps accounting for these lesions being 
ranked as more remyelinated at 2 weeks. The distribution of 
g-ratios compared to axon diameter for each group is shown 
in Suppl. Fig. 3.
Improvement of OPC recruitment and remyelination  
in Sema3AKD mice
As addition of rSema3A to demyelinated lesions both 
reduces OPC recruitment and remyelination, we next deter-
mined whether reducing Sema3A production in lesions 
could improve OPC recruitment and allow efficient remy-
elination. We generated transgenic mice by crossing mice 
expressing Cre recombinase in all cells with mice contain-
ing a floxed Sema3A gene, generating Sema3A-knockdown 
(KD) mice (see methods) (Fig. 9a–c). Sema3A−/− mice 
generated using the same floxed construct show some cra-
nial and peripheral nerve projection abnormalities [47], 
similarly to that found in other Sema3A−/− mice, but with 
no identified myelin abnormalities [1, 4]. The efficiency of 
Cre recombinase-mediated excision of DNA depends on 
the position of the loxp sites within the gene, and the dis-
tance between the sites [50], and in these transgenic mice, 
Sema3A protein expression in the brain was not completely 
knocked out, but instead reduced by around 60 % as com-
pared to control non-Cre containing littermates (Fig. 9c).
Demyelinated lesions were made in the corpus callosum 
of Sema3AKD mice and their littermate controls (express-
ing normal levels of Sema3A) as before and lesions exam-
ined 2 and 3 weeks after, as we predicted an increase in 
remyelination efficiency (Fig. 9d).
We counted the number of OPCs around and within the 
lesions to determine whether reducing Sema3A expression 
affects OPC migration, and observed an increase in OPCs 
on the lesioned side compared to the contralateral side at 
2 weeks in both control and Sema3AKD groups. However, 
the high number of OPCs on the lesioned side in Sema3AKD 
mice was maintained at 3 weeks, after OPC number nor-
malized in the controls, similarly to rSema3F treated lesions 
described above (Fig. 9e). Mature oligodendrocyte num-
bers (CC1+) increased in the control group over time, as 
compared to the unlesioned side as before. However, in the 
Sema3AKD group, there was not much change in the num-
ber of CC1+ cells around and within lesions as compared to 
the unlesioned side, suggesting that by these time points the 
number of CC1+ cells has already reached normal, correlat-
ing with remyelination of around 60 % of fibres already by 
2 weeks (Fig. 10b). There was little evidence of prolifera-
tion or apoptosis in lesions at 2 weeks after injection, and no 
difference between the two groups (Fig. 9f, g).
Assessment of remyelination using the same methods as 
before showed a clear increase in the percentage of fibres 
in a lesion that were remyelinated in Sema3AKD mice as 
compared to control mice, and no statistically significant 
difference in the thickness of the myelin sheaths, which 
remain thinner than normal in all groups. However, as in the 
Sema3F-treated group described before, there is a trend to 
increased myelin thickness in Sema3AKD mice, especially 
at smaller axon diameters (Fig. 10, Suppl. Fig. 4).
Discussion
We have shown that the number of OPCs present in MS 
lesions in postmortem brain is highly variable, both within 
lesions and between lesions. When compared with OPC 
counts in normal control white matter brain tissue, on aver-
age, within a lesion, we found lower than normal numbers 
of OPCs in 11/30 lesions (37 %), in the normal range in 
9/30 lesions (30 %), and increased numbers in 10/30 
lesions (33 %). This is in line with previous work [27]. We 
observed that the average OPC number correlated with the 
pathological subtype of the lesions, with most chronic active 
MS lesions (thought less likely to remyelinate) containing 
reduced numbers of OPCs, whereas most active MS lesions 
(thought most likely to remyelinate) contain more OPCs 
as compared to normal non-diseased white matter. Many 
chronic inactive lesions contain sufficient OPCs, suggest-
ing that the failure of remyelination in this lesion subtype 
may be due to an arrest of maturation. Most remyelinated 
lesions contain sufficient or increased numbers of OPCs, in 
line with their successful repair.
As this suggested that different levels of OPC migra-
tion to MS lesions may influence remyelination capacity, 
we examined the protein expression of known chemotac-
tic factors for OPCs—Sema3A and 3F within MS lesions. 
We found that although the chemoattractant Sema3F was 
expressed in both active and chronic active lesions, the 
chemorepellent Sema3A was mostly expressed in chronic 
active lesions, which mostly contain few OPCs. We had 
previously detected Sema3A mRNA in active MS lesions 
[54], but now describe little protein expression, and this dis-
crepancy is not unprecedented within the brain, as PMP22 
mRNA is expressed in oligodendrocytes, but no PMP22 
protein is present [22]. The receptors for these ligands 
(NP1 and NP2) are expressed by OPCs in and around all 
types of MS lesions, as well as by astrocytes and microglia/
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macrophage, suggesting that it is the differential expression 
of Sema3A and 3F in different MS lesions which confers 
different OPC recruitment patterns and their subsequent 
capacity to remyelinate (Fig. 11).
We tested this hypothesis using our in vivo mouse model 
for demyelination and remyelination, by manipulating the 
levels of Sema3A or 3F using recombinant protein injected 
into demyelinated lesions or by using a transgenic mouse 
with reduced Sema3A expression. We showed that increas-
ing Sema3F or reducing Sema3A expression increased 
OPC recruitment to lesions and accelerated remyelination, 
whereas increasing Sema3A in lesions decreased OPC 
recruitment and reduced remyelination, without seeing an 
effect on OPC proliferation, apoptosis or differentiation. 
This finding is discrepant with the previous finding of inhi-
bition of rat OPC differentiation with rSema3A [46], and 
Fig. 9  Transgenic knockdown 
of Sema3A increases recruit-
ment of OPCs after demyeli-
nation in vivo. a PCR shows 
presence of Cre-excised band 
in Sema3AKD mice. b Western 
blot shows reduced levels of 
Sema3A protein in Sema3AKD 
mice (GAPDH as loading con-
trol). c Densitometry measure-
ments of three western blots 
shows a significant (p < 0.001, 
t test) reduction in Sema3A 
protein expression as com-
pared to GAPDH expression, 
of around 60 %. d Strategy for 
in vivo experiment. e More 
nkx2.2+ oligodendroglial cells 
are present around and within 
lesions in Sema3AKD mice 
as compared to the unlesioned 
side at 2 and 3 weeks after the 
lesion. CC1+ oligodendroglial 
cells are relatively unchanged 
around and within lesions in 
Sema3AKD mice as compared 
to the unlesioned side at 2 
and 3 weeks after the lesion, 
suggesting that by these time 
points CC1+ number has 
already reached normal, cor-
relating with remyelination of 
around 60 % of fibres already 
by 2 weeks (see Fig. 10b) 
(mean ratio + SD asterisks on 
bars indicate value is signifi-
cantly different as compared to 
contralateral side (assigned 
value of 1), symbols above bars 
indicate significant differences 
between groups *p < 0.05, 
ϕp < 0.01, comparing treatments 
by ANOVA and Tukey’s post 
test). f There is no difference 
in proliferation (Ki67+ cells) 
or apoptosis (CC1+ cells) (g) 
within the lesion between the 
groups at 2 weeks after injection 
(Mean + SD, n > 20 sections 
from 5 mice per group)
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this may perhaps be explained by the use of different doses, 
at different times after demyelination and in a different spe-
cies. Furthermore, if the effect here is purely due to the fact 
that Sema3A reduces OPC differentiation in vivo, we would 
expect an increase or at least maintenance of OPC number 
in lesions due to an arrest of their differentiation into mature 
oligodendrocytes, and we saw a decreased number. Thus, 
although we cannot exclude some effect on OPC differen-
tiation, it is clear that this is not the key process affected 
in our model. One may speculate that factors promoting 
OPC migration will always inhibit differentiation, to avoid 
maturation to less motile differentiated oligodendroglial 
cells. However, CXCL1 has been shown to be a promoter 
of OPC migration, proliferation and differentiation [49, 
51], and so this is clearly over-simplistic, and the effect of 
a cytokine may depend on timing, concentration, receptor 
and downstream signalling molecule expression. An alter-
native explanation of our findings is that OPC migration to 
all lesions is adequate and similar but there is differential 
death of OPCs in MS lesions with more death in response to 
Sema3A and less in response to Sema3F. Although we did 
not see a change in numbers of OPC undergoing apoptosis 
at 2 weeks after lesion between control and treated groups 
when there is already a difference in OPC numbers, we can-
not exclude that death and clearance of OPCs may occur 
very fast and before this time point.
We previously showed that lentiviral delivery of Sema3F 
to a demyelinated lesion in a different mouse model 
improved remyelination [37], giving confidence in these 
results; an important factor considering the number of drug 
targets that look promising in initial publications, but which 
later fail to be repeated by pharmaceutical companies [39]. 
However, this is the first demonstration that Sema3A treat-
ment of demyelinated lesions in the mouse brain reduces 
OPC migration to the lesion and inhibits its subsequent 
remyelination. We hypothesize that the continued presence 
of Sema3A expression in human MS lesions, in contrast 
to the expression for a short time in mouse demyelinated 
lesions, may be one reason why mouse demyelinated lesions 
remyelinate efficiently and many human MS lesions do not. 
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Fig. 10  Transgenic knockdown of Sema3A in vivo changes remy-
elination efficiency. a Blinded ranking of remyelination shows more 
remyelination in Sema3AKD mice at 2 weeks compared to controls. 
Horizontal line represents median. *p < 0.05 using 1-way ANOVA 
and Tukey’s post test. b Graph of percentage of myelinated fibres in 
each group, counted from 10 fields of view per animal, and at least 
500 fibres per group. This shows that there is an increase in the num-
ber of fibres myelinated at both time points in the Sema3AKD group 
(mean ± SEM ***p < 0.001 using 1-way ANOVA and Tukey’s post 
test). c Graph showing that the average g-ratio per animal in each 
group is not significantly different in Sema3AKD animals at either 
time point, however, Sema3AKD mice (similarly to Sema3F-treated 
mice, see Fig. 8c) have a trend to thicker myelin by 3 weeks (lower 
g-ratio). Note that the y axis is inverted and does not start at zero, so 
that the graphs in a, b and c can be directly compared (mean ± SEM 
using 1-way ANOVA and Tukey’s post test). d Electron microscope 
photographs through lesions. Scale bar 1 μm
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This is one problem with using rodents as models for MS, 
as in contrast to humans, OPC recruitment and maturation 
normally occurs successfully in response to demyelination 
and remyelination does not normally fail.
Our finding that manipulation of OPC migration influ-
ences remyelination in a mouse model and the correlative 
human data suggests that failure of remyelination in a third 
of MS lesions is due to failure of OPC recruitment to these 
lesions. This reinstates OPC migration as an important tar-
get for therapies to improve remyelination in demyelinat-
ing disease, and introduces the Semaphorin pathway as a 
specific target. The most logical target is inhibition of the 
Sema3A pathway as this is expressed in those lesions that 
fail to remyelinate. The receptor for Sema3A is NP1, which 
is a transmembrane receptor present on OPCs, but also on 
macrophage/microglia [28] and T-regulatory cells (Treg) 
[53, 56]. We have confirmed expression of NP1 and NP2 
on microglia/macrophages in culture and in vivo in mouse 
and human (Suppl. Fig. 1 and data not shown) raising the 
possibility that Sema3A is also involved in influencing 
migration of these cells to lesions. Thus, drug inhibition of 
the Sema3A pathway may increase microglia/macrophage 
recruitment to demyelinated lesions, which may add further 
benefit as microglia/macrophage are essential for remy-
elination as they clear debris [20] and produce cytokines 
potentially useful for remyelination [31, 52]. Treg have 
now been identified in some MS lesions [13], and increas-
ing Treg number in models of EAE aids recovery from 
disease [44]. Therefore, Sema3A pathway inhibition may 
lead to an increased number of NP1+ Treg in MS lesions 
and reduce effector T cell responses locally. However, we 
cannot test this in our mouse model as we do not see a T 
cell response.
NP1 is a receptor for vascular endothelial growth factor 
(VEGF) as well as Sema3A, although these ligands occupy 
distinct binding sites which can be targeted separately by 
blocking antibodies [26, 33] and binding stimulates asso-
ciation with different co-receptors (plexins for Sema3A and 
VEGFR1/2 for VEGF), and different downstream signal-
ling pathways at least in neuronal cells (reviewed in [57]). 
The effect of VEGF signalling through the NP1 receptor 
on oligodendrocytes or on remyelination is not known, but 
NP1-null mice are embryonic lethal due to abnormalities 
of the development of the vascular system [19] and trans-
genic mice with mutation of the Sema3A binding site of 
NP1 only are viable [16], and so selective inhibition of the 
Sema3A binding site seems the preferred option. Sema3A-
NP1 binding has been shown to be tractable, at least with a 
large molecule inhibitor obtained from fungus, which has 
been used to improve peripheral nerve regeneration in cor-
neal transplants in mice [32], and axonal regeneration after 
spinal cord transection in rats [18].
This work shows the importance of OPC migration in the 
remyelination failure, giving a new group of therapeutic tar-
gets for aiding remyelination in MS patients, with the spe-
cific target of the Sema3A/NP1 pathway.
Fig. 11  Model summarizing 
Sema3A and Sema3F expres-
sion in different pathological 
subtypes of MS lesions and 
correlation with success or 
failure of OPC recruitment and 
subsequent remyelination
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